Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.3M Buy
634,756
+52,079
+9% +$1.36M 0.33% 52
2026
Q1
$16.4M Sell
582,677
-3,251
-0.6% -$86.6K 0.45% 39
2025
Q4
$14.6M Buy
585,928
+7,290
+1% +$184K 0.37% 50
2025
Q3
$14.7M Buy
578,638
+39,568
+7% +$977K 0.38% 41
2025
Q2
$13.1M Buy
539,070
+8,008
+2% +$187K 0.39% 43
2025
Q1
$13.1M Sell
531,062
-66,648
-11% -$1.74M 0.43% 41
2024
Q4
$15.9M Buy
+597,710
New +$16.2M 0.47% 29

Other funds holding PFE

Avanza Fonder's PFE Position: Q2 2026 in Review

Avanza Fonder increased its Pfizer (PFE) stake by 8.9% in Q2 2026, buying an estimated $1.36M and bringing the position to 634,756 shares worth $15.3M. The position accounts for 0.33% of the portfolio, ranked #52.

Avanza Fonder first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $16.4M in Q1 2026. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Avanza Fonder held 634,756 shares of Pfizer worth $15.3M as of Q2 2026.
  • Avanza Fonder bought 52,079 Pfizer shares in Q2 2026, an estimated $1.36M.
  • Pfizer made up 0.33% of Avanza Fonder's portfolio in Q2 2026, its #52 holding.
  • Avanza Fonder first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • Avanza Fonder's Pfizer position peaked at $16.4M in Q1 2026.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Avanza Fonder's 13F filing for Q2 2026, filed 17 Jul 2026.